Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.
Also called NCT01756430
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 238 participants
- Registry
-
NCT01756430
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01756430. Randomized; triple masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2013-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- Carvedilol SR 32mg, QD
- Intervention (Drug)
- Carvedilol SR 64mg, QD
- Intervention (Drug)
- Carvedilol IR 25mg, QD
- Intervention (Drug)
- Carvedilol IR 25mg, BID
- Lead sponsor
- Chong Kun Dang Pharmaceutical
Record details
- Record id
cardio:ct-nct01756430- Content hash
f9fd7ce1ca57f7419fb965434896d94c7261a92f863d9f4fb5697bb148808956